Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
PHARMACEUTICAL COMPOSITION INHIBITING PRODUCTION OF HEPATITIS B VIRUS PROTEIN, PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HEPATITIS B, AND SCREENING METHOD
Document Type and Number:
WIPO Patent Application WO/2020/196738
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing: a pharmaceutical composition that is useful as a novel anti-hepatitis B virus agent; and a screening method. The present invention provides a pharmaceutical composition that inhibits the production of a hepatitis B virus protein, and that is characterized by inhibiting the expression or the function of a protein belonging to the YTHDC family.

Inventors:
HABA RYOTA (JP)
SHIMANE KAZUKI (JP)
YAMASHITA NOZOMI (JP)
Application Number:
PCT/JP2020/013625
Publication Date:
October 01, 2020
Filing Date:
March 26, 2020
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
FUJIFILM CORP (JP)
International Classes:
A61K45/00; A61K31/7088; A61K35/76; A61K35/761; A61K38/00; A61K48/00
Domestic Patent References:
WO2010134939A22010-11-25
Foreign References:
JP2018503663A2018-02-08
Other References:
ZHANG, Y. ET AL.: "RNA-binding Protein YTHDF3 Suppresses Interferon-Dependent Antiviral Responses by Promoting FOX03 Translation.", PROC NATL ACAD SCI USA., vol. 116, no. 3, 15 January 2019 (2019-01-15), pages 976 - 981, XP055743130
IMAM, H. ET AL.: "N6-methyladenosine modification of hepatitis B virus RNA differentially regulates the viral life cycle.", PROC NATL ACAD SCI USA., vol. 115, no. 35, 2018, pages 8829 - 8834, XP055743136
YE, F. ET AL.: "Kaposi's Sarcoma-Associated Herpesvirus Utilizes and Manipulates RNA N 6- Adenosine Methylation To Promote Lytic Replication.", J VIROL., vol. 91, no. 16, 2017, pages 1 - 21, XP055743141
BALACCO, DL ET AL.: "The m6A Writer: Rise of a Machine for Growing Tasks.", BIOCHEMISTRY, vol. 58, 5 February 2019 (2019-02-05), pages 363 - 378, XP055743144
TANAKA ET AL., MODERN MEDIA, vol. 54, no. 12, pages 347 - 352
BROUW ET AL., IMMUNOLOGY, vol. 126, 2008, pages 280 - 289
VANLANDSCHOOT ET AL., JOURNAL OF GENERAL VIROLOGY, vol. 83, 2002, pages 1281 - 1289
LIAO ET AL., GENOMICS PROTEOMICS BIOINFORMATICS, vol. 16, 2018, pages 99 - 107
IMAM ET AL., PROC NATL ACAD SCI USA, vol. 115, no. 35, 2018, pages 8829 - 8834
SHARP ET AL., SCIENCE, vol. 287, 2000, pages 2431 - 2432
ZAMORE ET AL., CELL, vol. 101, 2000, pages 25 - 33
TUSCHL ET AL., GENES & DEVELOPMENT, vol. 13, 1999, pages 3191 - 3197
OZAWA ET AL., DRUG DELIVERY SYSTEM, vol. 22, no. 6, 2007, pages 643 - 650
JINEK ET AL., SCIENCE, vol. 337, 2012, pages 816 - 821
LIAO ET AL., GENOMICS PROTEOMICS BIOINFORMATICS, vol. 16, pages 99 - 107
PROC NATL ACAD SCI USA, vol. 84, 1987, pages 1005 - 1009
NAT CELL BIOL, vol. 5, 2003, pages 489 - 490
Attorney, Agent or Firm:
SIKS & CO. (JP)
Download PDF: